BRAF inhibitors in clinical oncology
Van Morris¹ and Scott Kopetz²*

Addresses: ¹Division of Cancer Medicine and ²Division of Gastrointestinal Medical Oncology, The University of Texas – M.D. Anderson Cancer Center, Houston, TX
* Corresponding author: Scott Kopetz (SKopetz@mdanderson.org)

F1000Prime Reports 2013, 5:11 (doi:10.12703/P5-11)

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/5/11

Abstract
Activating mutations of the BRAF oncogene are present in approximately 5-10% of all human malignancies and lead to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. The introduction of BRAF inhibitors has greatly improved the short term prospects of some patients with these tumors, but the tumors tend to become resistant to therapy with time by activating alternative signaling pathways. Consequently, combination strategies with drugs that block not only the primary mutated BRAF kinase but also the alternative pathways implicated in development of resistance may represent a better strategy for improving survival in patients with tumors harboring BRAF mutations.

Introduction
The identification of mutations that drive signaling pathways critical to tumor growth and survival has led to a new taxonomy in oncology in which cancers are classified according to the molecular aberration present. One pathway of particular interest is the MAPK pathway, which is estimated to be dysregulated in approximately 50% of all human malignancies [1,2]. RAF is one kinase along this signaling cascade that, once activated, phosphorylates MEK [3,4], which in turn triggers activation of MAPK and leads to downstream promotion of cell growth [5].

Activating mutations of the BRAF oncogene are present in approximately 5-10% of all human malignancies [2] and lead to constitutive activation of the MAPK pathway [6,7]. The most common mutation of BRAF is a valine-to-glutamic acid substitution at codon 600 (V600E), which has been implicated as the driving factor in subpopulations of patients with melanoma, colorectal cancer, papillary thyroid cancer, non-small cell lung cancer (NSCLC), and ovarian cancer [2,8-16]. The introduction of inhibitors of activated BRAF represents an important therapeutic approach in recent oncological care. This review will discuss the successes and early challenges of BRAF inhibitors in clinical oncology.

BRAF inhibitors in melanoma
BRAF V600E mutations are found in approximately 50% of all cutaneous melanomas [2,17]. Understanding the importance of this mutation in the oncologic behavior of melanoma has led to the development of vemurafenib, an inhibitor of the kinase domain of mutated BRAF that, in vitro, blocks signaling of the MAPK pathway and decreases melanoma cell proliferation [18-20]. A randomized phase III trial that compared vemurafenib to dacarbazine, then a standard first-line treatment for stage IV disease, in 675 patients with previously untreated metastatic melanoma showed an improvement in overall survival rate at 6 months (84% versus 64%) for those given the former therapy [21]. Patients receiving the BRAF inhibitor were 63% more likely to be alive at the time of interim analysis (hazard ratio 0.37, 95% confidence interval 0.26-0.55, p < 0.001), with an associated improvement in median progression-free survival from 1.6 months to 5.3 months. The development of keratoacanthomas and cutaneous squamous cell carcinomas, the most common grade III toxicity occurring in approximately 25% of trial participants, appeared within 2-3 months of treatment initiation, but can be readily excised without the need for dose modification of vemurafenib. This side effect is thought to be caused by the paradoxical activation of wildtype RAF.
kinases to BRAF inhibitor therapy [22]. More recently, results were published of another phase III trial comparing the BRAF inhibitor dabrafenib (a newer-generation, reversible kinase inhibitor of V600E-mutant BRAF with a higher affinity than the wildtype enzyme for mutant BRAF) to dacarbazine [22]. Here again, progression-free survival was increased in the arm receiving the BRAF inhibitor (5.1 months versus 2.7 months, respectively, p < 0.001), but grade III toxicities were likewise uncommon in this group, at only 4%.

Despite the initial successes of vemurafenib, tumors inevitably develop resistance and circumvent BRAF inhibition, a theme unfortunately common with the use of single-agent targeted therapeutic agents. Resistance to vemurafenib seemingly occurs because of alternative activation of the MAPK pathway despite BRAF inhibition, and multiple mechanisms driving activation of this signaling pathway have been described [23-26]. To that end, given the oncologic ‘addiction’ of melanoma cells to this pathway [27], a phase I/II trial of dabrafenib and trametinib (a selective MEK inhibitor) was recently completed in previously untreated patients with metastatic melanoma [28]. Here, those receiving the combination of both drugs showed a 3.6 month improvement in progression-free survival relative to those treated with dabrafenib alone (9.4 months versus 5.8 months, p < 0.001), a finding suggesting that dual blockade at multiple steps of this pathway may delay the onset of resistance. Phase III trials are currently ongoing, and it will be interesting to see whether or not dual inhibitor therapy will replace BRAF inhibitor monotherapy as the standard of care for patients with BRAF-mutant metastatic melanoma.

**BRAF inhibitors in colorectal cancer**

Approximately 10% of all patients with colorectal cancer have tumors with an activating BRAF mutation, with the V600E mutation being the most common. BRAF-mutant tumors in colorectal cancer are associated with older age, female gender, right-sided primary colon tumors, gene hypermethylation, and microsatellite instability [29,30]. Responses to systemic chemotherapy are considered poor in BRAF-mutant tumors [31-34], and so it is not surprising that overall survival is especially grim in this subpopulation [35,36], with one recent retrospective review reporting a 10.4 months versus 34.7 month overall survival among patients with BRAF-mutant and BRAF wildtype metastatic colorectal cancer, respectively [37].

A phase IB study of vemurafenib reported a response rate in only 5% (one partial response, no complete responses) among twenty patients with metastatic colorectal cancer evaluated for radiographic response. Median progression-free survival was only 3.7 months in this study [38]. Several patients did demonstrate a mixed response pattern in their various tumor sites, suggesting that BRAF inhibitors may serve as the backbone for additional therapy as more of the underlying biology of this disease is uncovered. Likewise, the prospect of translating the successes of concomitant BRAF/MEK inhibition noted in the BRAF-mutant metastatic melanoma seems less promising for colorectal cancer. Initial data presented at the 2012 ASCO Annual Convention reported a response rate of only 5% (1 partial response among 20 patients evaluated, 10 with stable disease) in patients with BRAF-mutated metastatic colorectal cancer treated with dabrafenib and trametinib together [39].

Interestingly, the reason for resistance to therapy in BRAF-mutated colorectal cancer appears to be continued activation of critical signaling pathways. Two groups independently reported that blockade of BRAF causes rapid feedback activation of epidermal growth factor receptor (EGFR) [40,41], which, upon phosphorylation triggers sustained MAPK signaling and cell proliferation via activation of RAS and CRAF. In vitro, blocking EGFR activity with cetuximab, a monoclonal antibody to EGFR, restores sensitivity to vemurafenib. Clinical trials of the combination of vemurafenib and cetuximab in metastatic BRAF-mutated colorectal cancer are currently underway. Additionally, resistance to BRAF inhibition may also develop by activation of other pathways. Recently, our group has shown that, in cell lines, colorectal cancer demonstrates higher levels of phosphatidylinositol-3 kinase (PI3K)/Akt signaling (implicated in anti-apoptotic behavior) than melanoma and that BRAF-mutated colorectal cells display less sensitivity in vitro to vemurafenib when concomitant PTEN or PI3K mutations are present [42]. In mice xenografts, treatment with vemurafenib and a PI3K inhibitor lead to greater inhibition of tumor growth than vemurafenib alone, a finding suggesting that targeting compensatory pathways may provide an improved approach to treating patients whose tumors are driven by activating BRAF mutations.

**BRAF mutations in papillary thyroid cancer**

Activating BRAF mutations occur in approximately 45-50% of all papillary thyroid cancers [43] and are associated with extrathyroidal extension, lymph node metastases, and an overall poorer prognosis than BRAF wildtype tumors [44-46]. However, even though the seminal phase 1 study with vemurafenib showed a complete or partial response in all three patients with papillary thyroid cancer [47], to date, no clinical trials have been reported detailing the effects of BRAF inhibitor
therapies on patients specifically with BRAF-mutant papillary thyroid tumors. Phase II trials are currently enrolling patients with metastatic papillary thyroid cancer for treatment with vemurafenib, and with locally advanced disease using vemurafenib as a neoadjuvant approach with which to improve surgical resectability.

**BRAF mutations in non-small cell lung cancer**

BRAF mutations have been reported to occur in 3% of lung adenocarcinomas [16,48]. Essentially all patients harboring these mutations are active or former tobacco smokers [48-50]. Even though V600E substitutions are the most common among BRAF mutations, one series reported a 39% prevalence of G469A substitutions in lung cancer [48]. Whether or not V600E-specific kinase inhibitors will exhibit clinical improvements in patients with a spectrum of different BRAF point mutations has yet to be determined, although clinical trials are currently underway (see Table 1 below).

**Inhibitors in clinical development**

Following the results of the aforementioned phase III trial, vemurafenib was approved by the U.S. Food and Drug Administration in 2011 for use in patients with BRAF-mutant metastatic melanoma. The use of vemurafenib outside this context is otherwise limited to participants in clinical trials, although several trials investigating other BRAF inhibitors have recently been completed (results pending) or are actively accruing enrollment.

**Future directions**

Although the significance of an activating BRAF mutation is now well appreciated in clinical oncology, treating these tumors with targeted therapies has proven a challenge. Regardless of initial response to BRAF inhibitors, tumors eventually develop resistance to these agents, due to activation of various alternative signaling pathways that perpetuate cell proliferation and survival. One recent commentary proposed that the onset of drug resistance in tumors may be delayed with multi-drug regimens targeting multiple oncogenic substrates, akin to the approach seen in four-drug therapies for tuberculosis and in antiretroviral therapy with HIV [51]. Indeed, using combination strategies with drugs that block not only the primary mutated BRAF kinase but also the pathways most commonly implicated in development of resistance may represent a better strategy for improving survival outcomes in patients with tumors harboring BRAF mutations.

### Table 1. BRAF inhibitors in development

| BRAF inhibitor | Company | Phase | Patients included | Study description |
|---------------|---------|-------|-------------------|-------------------|
| BMS-908662 [52] | Bristol-Myers Squibb | I/II trial completed | Advanced or metastatic colorectal cancer with BRAF or KRAS mutations | To identify the maximum tolerated dose of BMS-908662 in combination with cetuximab; to evaluate tumor response with the BRAF inhibitor alone or in combination with cetuximab |
| LGX818 [53] | Novartis | I/II | Advanced solid tumors with V600 BRAF mutations | To determine the maximum tolerated dose and the efficacy of LGX818 in combination with a MEK inhibitor |
| PLX3603 [54] | Hofmann-LaRoche | I | Advanced solid tumors with BRAF mutations | To evaluate the safety, tolerability, and pharmacokinetics of PLX3603 |
| RAF265 [55] | Novartis | Ib | 1. Advanced solid tumors with BRAF V600 mutations 2. Advanced solid tumors with RAS mutations | To determine the maximum tolerated dose safety and tolerability of RAF265 in combination with the MEK inhibitor MEK162; to determine initial anti-tumor efficacy in two separate patient populations |
| ROS185426 [56] | Hofmann-LaRoche | II | Unresectable or metastatic papillary thyroid cancer harboring a BRAF mutation and resistant to radioactive iodine therapy | To study the safety and efficacy of ROS185426 as a single agent therapy |
| GSK2118436 [57] | GlaxoSmithKline | II | Advanced stage/metastatic NSCLC with a V600E BRAF mutation that progressed after platinum chemotherapy | To assess the efficacy, safety, and tolerability of GSK2118436 as a single-agent therapy |
Abbreviations
EGFR, epidermal growth factor receptor; MAPK, mitogen-activated protein kinase; NSCLC, non-small cell lung cancers; PI3K, phosphatidylinositol-3 kinase.

Disclosures
The authors declare that they have no disclosures.

References
1. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003, 30:105-16.

2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Walterscourses H, Garnett MJ, Bottomley W, Davis N, Nicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-54.

3. Papin C, Denouel A, Calothy G, Eychène A: Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 1996, 12:2213-21.

4. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ: Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997, 272:4378-83.

5. Brunet A, Pagès G, Pousset S: Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994, 9:3379-87.

6. Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature 2004, 445:851-7.

7. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:853-67.

8. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2002, 88:5399-404.

9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-7.

10. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. Braf mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-7.

11. Singer G, Old K, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih I: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-6.

12. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003, 22:9192-6.

13. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003, 22:4655-7.

14. Wang L, Cunningham JM, Winters JL, Guenther MJ, French AJ, Boardman LA, Burgart LJ, Mcdonnell SK, Schaid DJ, Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003, 63:5209-12.

15. Naoki K, Chen T, Richards WG, Sugarbaker DJ, Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62:7001-3.

16. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrer R, Einhorn H, Herlyn M, Minna J, Nicholson A, Roth JA, Albeda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6977-7000.

17. Houben R, Becker JC, Kapell A, Terheyden P, Bröcker E, Goetz R, Rapp UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Cancer Res 2004, 316.

18. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Hall S, Hsueh T, Mok S, Søndergaard JN, Nazarian R, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe E, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Koya RC, Boardman LA, Burgart LJ, McDonnell SK, Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003, 63:5209-12.

19. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Saegar H, MacConaill LE, Barretina JG, Kehoe E, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Koya RC, Boardman LA, Burgart LJ, McDonnell SK, Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003, 63:5209-12.

20. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haas NK, Sproesser K, Li L, Slamley KSH, Fong D, Zhu Y, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Lui C, Setzachagul C, Shellroo E, Canwell J, Kim S, Schlessinger J, Zhang KY, West BL, et al.: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U.S.A 2008, 105:3041-6.

21. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbé C, Jouary T, Schadendorf D, Ribas A, O'Day S, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib...
in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-16.

22. Hauchard A, Grob J, Demidov LV, Jouary T, Gutzner R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karazewzewska B, Mauch C, Chirion-Sileni V, Martin A, Swann P, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB: Dabrafenib in BRAF-mutated metastatic melanoma: a multi-centre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-65.

23. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponio G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-72.

24. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M, Attar N, Szegel H, Chodot T, Nelson SF, MacArthur G, Somasundaram R, Fukunaga-Kalabis M, Nazarian R, Shi H, Kong X, Koya RC, Lee H, Chen Z, Lee M, Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponio G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-72.

25. Villanueva J, Vultor A, Demidov LV, Jouary T, Gutzner R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karazewzewska B, Mauch C, Chirion-Sileni V, Martin A, Swann P, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB: Dabrafenib in BRAF-mutated metastatic melanoma: a multi-centre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-65.

26. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M, Attar N, Szegel H, Chodot T, Nelson SF, MacArthur G, Somasundaram R, Fukunaga-Kalabis M, Nazarian R, Shi H, Kong X, Koya RC, Lee H, Chen Z, Lee M, Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponio G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-72.

27. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M, Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponio G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-72.

28. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefferd RF, Somas J, Hamid O, Schuchter L, Ceblon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined BRAF and MEK inhibition in BRAF V600E mutations. Nature 2011, 468:387-90.

29. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6297-8.

30. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefferd RF, Somas J, Hamid O, Schuchter L, Ceblon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined BRAF and MEK inhibition in BRAF V600E mutations. Nature 2011, 468:387-90.

31. de Roock W, Claes B, Bernasconi D, de Schutter J, Biesmans B, Fountzilas G, Kolagaras KT, Koutola V, Papanikola D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Fratini M, Molinari F, Saletsi P, de Dossos S, Martinin M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-62.

32. van Cutsen E, Kohne C, Láng I, Folprecht G, Nowacki MP, Cascini S, Schhepotin I, Muarel J, Cunningham D, Teijpar S, Schlüchting M, Zubel A, Cerk I, Rougier P, Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-9.

33. Price T, Gardening JE, Lee CT, Weichhardt A, Townsend A, Wrin JW, Chua A, Shivashis A, Cummins MM, Murone C, Tebbutt NC: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From The Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011, 29:2675-82.

34. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestri N, Rulli E, Fioriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wildtype metastatic colorectal cancer. Br J Cancer 2009, 101:715-21.

35. Sougakos J, Philips J, Wang R, Marwah S, Silver M, Tzird M, Silver J, Orgino S, Khoshmansad K, Wu K, Freed E, Meyerhardt JA, Saridaki Z, Georgoulas V, Finkelstein D, Fuchs S, Kulke MH, Shvadras RA: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-72.

36. Tol J, Nagtegaal ID, Punt CJJA: BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361:98-9.

37. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu D, Agarwal A, Maru DM, Sieber O, Desai J, Sanger J, et al.: Impact of BRAF mutation and prognosis in metastatic colorectal cancer. Br J Cancer 2011, 101:4623-32.

38. Kopetz S, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010, 28(15):suppl 3534.

39. Corcoran R, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2128436) plus MEK inhibitor trametinib (GSK1120212). J Clin Oncol 2012, 30(15):suppl 3528.

40. Corcoran R, Brown R, Della Pelle P, Diaz-Sangatta D, Hung KE, Flaherty KT, Piris A, Wargo JA, Selijan J, Mino-Kendon M, Engelman JA: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012, 2:227-35.

41. Praghallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zechin D, Beijersberg RL, Bardelli A, Bernards R: Unresponsiveness of
colon cancer to Braf(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-3.

42. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YNV, Jiang Z, Wustuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S: Resistance to Braf Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clin Cancer Res 2013.

43. Xing M: Braf mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-62.

44. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T: Clinical significance of Braf(V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 2007, 27:3645-9.

45. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R: Braf(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15:191-205.

46. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya K: Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008, 93:611-8.

47. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated Braf in metastatic melanoma. N Engl J Med 2010, 363:809-19.

48. Paik PK, Arcilla ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ: Clinical characteristics of patients with lung adenocarcinomas harboring Braf mutations. J Clin Oncol 2011, 29:2946-51.

49. Sasaki H, Shitara M, Yokota K, Okuda K, Hikosaka Y, Moriyama S, Yano M, Fujiy Y: Braf and erbb2 mutations correlate with smoking status in lung cancer patients. Exp Ther Med 2012, 3:771-5.

50. Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang C, Date H: Clinical significance of Braf gene mutations in patients with non-small cell lung cancer. Anticancer Res 2011, 31:4619-23.

51. Glickman MS, Sawyer CL: Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012, 148:1089-98.

52. Bristol-Myers Squibb: Safety and efficacy study of BMS-908662 alone or in combination with cetuximab in subjects with K-RAS or B-RAF mutation positive advanced or metastatic colorectal cancer. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT01086267

53. Novartis Pharmaceuticals: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With Braf Dependent Advanced Solid Tumors. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT01543698

54. Hoffmann-La Roche: A Study of ROS212054 (PLX3603) in Patients With Braf V600-mutated Advanced Solid Tumours. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT0143753

55. Novartis Pharmaceuticals: MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BrafV600E Mutations. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT01352273

56. Hoffmann-La Roche: A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the Braf V600 Mutation. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT01286753

57. GlaxoSmithKline: A Phase II Study of the Selective Braf Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and Braf Mutations. In: clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (U.S.), 2000-11/2012. Available from: www.clinicaltrials.gov/NCT0136634